Pfizer Inc. (PFE) 10-Year Financial Performance & Capital Metrics

PFE •

HealthcareLarge PharmaVaccines and plasma-derived therapies

AboutPfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.Show more

Revenue $62.58B -1.6%
EBITDA $20.34B -13.4%
Net Income $7.77B -3.1%
EPS (Diluted) 1.36 -3.5%
Gross Margin 70.33% +6.9%
EBITDA Margin 32.51% -12.0%
Operating Margin 24.67% -4.8%
Net Margin 12.42% -1.5%
ROE 8.56% -5.1%
ROIC 9.35% +17.9%
Debt/Equity -
Interest Coverage 5.78 +8.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓14 consecutive years of dividend growth
✓Healthy 5Y average net margin of 17.4%
✓Trading near 52-week high

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y2.51%

5Y8.48%

3Y-14.56%

TTM-1.65%

Profit (Net Income) CAGR

10Y1.1%

5Y-3.24%

3Y-37.2%

TTM-3.12%

EPS CAGR

10Y2.02%

5Y-3.51%

3Y-37.12%

TTM-3.42%

ROCE

10Y Avg10.78%

5Y Avg12.62%

3Y Avg7.32%

Latest9.35%

Peer Comparison

Vaccines and plasma-derived therapies

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
GRFSGrifols, S.A.	2.35B	9.10	33.54	9.41%	4.96%	4.92%	26.64%	1.17
PFEPfizer Inc.	157.21B	27.65	20.33	-1.65%	12.42%	8.35%
SNYSanofi	117.53B	48.66	20.32	5.49%	16.72%	10.9%	8.92%	0.30
MRKMerck & Co., Inc.	307.22B	123.78	17.00	1.31%	28.08%	35.17%
GSKGSK plc	118.65B	59.13	16.16	1.83%	17.86%	35.83%	6.6%	1.11

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	52.82B	52.55B	53.65B	41.17B	41.65B	81.29B	100.33B	59.55B	63.63B	62.58B
Revenue Growth %	8.13%	-0.53%	2.1%	-23.25%	1.16%	95.16%	23.43%	-40.64%	6.84%	-1.65%
Cost of Goods Sold+	15.95B	15.78B	16.01B	12.62B	11.77B	34.41B	38.24B	29.21B	21.78B	18.57B
COGS % of Revenue	30.2%	30.03%	29.84%	30.66%	28.26%	42.33%	38.11%	49.05%	34.23%	29.67%
Gross Profit+	36.87B	36.77B	37.64B	28.55B	29.88B	46.88B	62.09B	30.34B	41.85B	44.01B
Gross Margin %	69.8%	69.97%	70.16%	69.34%	71.74%	57.67%	61.89%	50.95%	65.77%	70.33%
Gross Profit Growth %	3.29%	-0.27%	2.37%	-24.15%	4.66%	56.88%	32.46%	-51.14%	37.92%	5.18%
Operating Expenses+	22.6B	22.38B	22.35B	21.04B	20.8B	26.08B	24.54B	25.05B	25.36B	28.58B
OpEx % of Revenue	42.78%	42.59%	41.66%	51.1%	49.93%	32.09%	24.46%	42.06%	39.86%	45.67%
Selling, General & Admin	14.76B	14.73B	14.38B	12.67B	11.4B	12.25B	13.12B	14.47B	14.73B	13.35B
SG&A % of Revenue	27.93%	28.04%	26.81%	30.78%	27.37%	15.07%	13.07%	24.3%	23.15%	21.33%
Research & Development	7.84B	7.64B	7.97B	8.36B	9.39B	13.83B	11.43B	10.58B	10.74B	11.98B
R&D % of Revenue	14.84%	14.55%	14.85%	20.31%	22.56%	17.01%	11.39%	17.76%	16.88%	19.14%
Other Operating Expenses	0	0	0	0	0	0	0	0	-105M	3.25B
Operating Income+	14.27B	14.39B	15.29B	7.51B	9.09B	20.79B	37.55B	5.29B	16.48B	15.44B
Operating Margin %	27.02%	27.39%	28.5%	18.24%	21.81%	25.58%	37.43%	8.89%	25.91%	24.67%
Operating Income Growth %	7.36%	0.82%	6.24%	-50.87%	20.96%	128.87%	80.58%	-85.91%	211.47%	-6.35%
EBITDA+	20.03B	20.66B	21.67B	13.31B	13.77B	25.98B	42.61B	11.58B	23.5B	20.34B
EBITDA Margin %	37.92%	39.32%	40.4%	32.32%	33.05%	31.97%	42.47%	19.45%	36.93%	32.51%
EBITDA Growth %	8.55%	3.14%	4.9%	-38.61%	3.46%	88.75%	64%	-72.82%	102.87%	-13.42%
D&A (Non-Cash Add-back)	5.76B	6.27B	6.38B	5.79B	4.68B	5.19B	5.06B	6.29B	7.01B	4.91B
EBIT	9.54B	13.57B	13.2B	13.06B	8.49B	25.6B	35.97B	3.27B	11.11B	10.19B
Net Interest Income+	-716M	-879M	-983M	-1.35B	-1.38B	-1.25B	-987M	-585M	-2.55B	-2.07B
Interest Income	470M	391M	333M	225M	73M	36M	251M	1.62B	545M	603M
Interest Expense	1.19B	1.27B	1.32B	1.57B	1.45B	1.29B	1.24B	2.21B	3.09B	2.67B
Other Income/Expense	-5.92B	-2.09B	-3.4B	3.97B	-2.05B	3.52B	-2.82B	-4.23B	-8.46B	-7.92B
Pretax Income+	8.35B	12.3B	11.88B	11.48B	7.04B	24.31B	34.73B	1.06B	8.02B	7.52B
Pretax Margin %	15.81%	23.42%	22.15%	27.9%	16.89%	29.91%	34.61%	1.78%	12.61%	12.02%
Income Tax+	1.12B	-9.05B	706M	618M	370M	1.85B	3.33B	-1.11B	-28M	-266M
Effective Tax Rate %	86.4%	173.14%	93.84%	141.69%	130.17%	91.1%	90.31%	201.61%	99.96%	103.32%
Net Income+	7.21B	21.3B	11.15B	16.27B	9.16B	22.15B	31.36B	2.13B	8.02B	7.77B
Net Margin %	13.66%	40.55%	20.79%	39.52%	21.99%	27.25%	31.26%	3.58%	12.6%	12.42%
Net Income Growth %	3.57%	195.29%	-47.65%	45.91%	-43.72%	141.81%	41.62%	-93.2%	276%	-3.12%
Net Income (Continuing)	7.23B	21.35B	11.18B	10.87B	6.67B	22.46B	31.4B	2.17B	8.05B	7.79B
Discontinued Operations	17M	-1M	10M	5.43B	2.53B	-268M	-1M	0	11M	25M
Minority Interest	296M	348M	351M	303M	235M	262M	256M	274M	294M	0
EPS (Diluted)+	1.17	3.52	1.87	2.87	1.63	3.88	5.47	0.37	1.41	1.36
EPS Growth %	5.09%	200.58%	-46.94%	53.67%	-43.29%	138.58%	41.01%	-93.22%	279.85%	-3.55%
EPS (Basic)	1.18	3.57	1.90	2.92	1.65	3.95	5.59	0.38	1.42	1.36
Diluted Shares Outstanding	6.16B	6.06B	5.98B	5.67B	5.63B	5.71B	5.73B	5.71B	5.7B	5.69B
Basic Shares Outstanding	6.09B	5.97B	5.87B	5.57B	5.55B	5.6B	5.61B	5.64B	5.66B	5.68B
Dividend Payout Ratio	101.41%	35.95%	71.53%	49.43%	92.15%	39.41%	28.64%	433.52%	118.6%	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	38.95B	41.14B	49.93B	32.8B	35.07B	59.69B	51.26B	43.33B	50.36B	0
Cash & Short-Term Investments	17.85B	19.99B	18.83B	9.65B	12.22B	31.07B	22.73B	12.69B	20.48B	0
Cash Only	2.6B	1.34B	1.14B	1.12B	1.79B	1.94B	416M	2.85B	1.04B	0
Short-Term Investments	15.26B	18.65B	17.69B	8.53B	10.44B	29.13B	22.32B	9.84B	19.43B	0
Accounts Receivable	11.27B	11.27B	11.4B	9.51B	11.18B	15.74B	14.53B	15.54B	14.78B	0
Days Sales Outstanding	77.85	78.29	77.56	84.29	97.95	70.7	52.86	95.27	84.77	-
Inventory	6.78B	7.58B	7.51B	7.07B	8.05B	9.06B	8.98B	10.19B	10.85B	0
Days Inventory Outstanding	155.18	175.32	171.19	204.37	249.49	96.08	85.72	127.31	181.84	-
Other Current Assets	3.05B	2.3B	12.19B	6.58B	3.65B	3.82B	5.02B	4.91B	4.25B	0
Total Non-Current Assets+	132.67B	130.65B	109.5B	134.69B	119.16B	121.78B	145.94B	183.17B	163.04B	0
Property, Plant & Equipment	13.32B	13.87B	13.38B	12.97B	13.74B	14.88B	16.27B	18.94B	18.39B	0
Fixed Asset Turnover	3.97x	3.79x	4.01x	3.17x	3.03x	5.46x	6.17x	3.14x	3.46x	-
Goodwill	54.45B	55.95B	53.41B	48.2B	49.56B	49.21B	51.38B	67.78B	68.53B	0
Intangible Assets	52.65B	48.74B	35.21B	33.94B	28.34B	25.15B	43.37B	64.9B	55.41B	0
Long-Term Investments	7.12B	7.01B	2.77B	20.15B	20.26B	21.53B	15.07B	15.37B	2.23B	0
Other Non-Current Assets	3.32B	3.23B	2.8B	17.63B	4.57B	7.68B	13.16B	12.47B	9.82B	0
Total Assets+	171.62B	171.8B	159.42B	167.49B	154.23B	181.48B	197.21B	226.5B	213.4B	0
Asset Turnover	0.31x	0.31x	0.34x	0.25x	0.27x	0.45x	0.51x	0.26x	0.30x	-
Asset Growth %	2.48%	0.11%	-7.2%	5.06%	-7.92%	17.67%	8.67%	14.85%	-5.79%	-100%
Total Current Liabilities+	31.11B	30.43B	31.86B	37.3B	25.92B	42.67B	42.14B	47.79B	42.99B	0
Accounts Payable	4.54B	4.66B	4.67B	3.89B	4.28B	5.58B	6.81B	6.71B	5.63B	0
Days Payables Outstanding	103.78	107.72	106.57	112.39	132.81	59.16	64.99	83.84	94.4	-
Short-Term Debt	10.66B	9.94B	8.84B	16.19B	2.7B	2.24B	2.93B	10.35B	6.95B	0
Deferred Revenue (Current)	0	0	0	0	1.11B	3.07B	2.52B	2.7B	1.51B	0
Other Current Liabilities	13.54B	13.32B	15.04B	14.14B	14.61B	28.27B	25.98B	23.32B	23.2B	0
Current Ratio	1.25x	1.35x	1.57x	0.88x	1.35x	1.40x	1.22x	0.91x	1.17x	-
Quick Ratio	1.03x	1.10x	1.33x	0.69x	1.04x	1.19x	1.00x	0.69x	0.92x	-
Cash Conversion Cycle	129.25	145.89	142.17	176.27	214.63	107.62	73.59	138.74	172.21	-
Total Non-Current Liabilities+	80.66B	69.71B	63.81B	66.84B	64.84B	61.34B	59.15B	89.42B	81.9B	-93.1B
Long-Term Debt	30.4B	32.67B	32.91B	34.65B	35.57B	34.76B	31.93B	60.5B	57.41B	0
Capital Lease Obligations	-12.17B	-27B	-21.35B	1.03B	0	0	0	0	2.29B	0
Deferred Tax Liabilities	30.75B	3.9B	3.7B	5.58B	4.06B	349M	1.02B	640M	2.12B	0
Other Non-Current Liabilities	19.51B	33.15B	27.2B	26.54B	25.2B	26.24B	26.2B	28.28B	20.09B	-93.1B
Total Liabilities	111.78B	100.14B	95.66B	104.15B	90.76B	104.01B	101.29B	137.21B	124.9B	-93.1B
Total Debt+	41.06B	42.61B	41.74B	50.84B	38.27B	37B	34.86B	70.84B	66.99B	0
Net Debt	38.47B	41.26B	40.61B	49.72B	36.49B	35.05B	34.44B	67.99B	65.95B	0
Debt / Equity	0.69x	0.59x	0.65x	0.80x	0.60x	0.48x	0.36x	0.79x	0.76x	-
Debt / EBITDA	2.05x	2.06x	1.93x	3.82x	2.78x	1.42x	0.82x	6.12x	2.85x	-
Net Debt / EBITDA	1.92x	2.00x	1.87x	3.74x	2.65x	1.35x	0.81x	5.87x	2.81x	-
Interest Coverage	12.04x	11.33x	11.62x	4.77x	6.27x	16.11x	30.33x	2.40x	5.33x	5.78x
Total Equity+	59.84B	71.66B	63.76B	63.45B	63.47B	77.46B	95.92B	89.29B	88.5B	93.1B
Equity Growth %	-7.94%	19.75%	-11.02%	-0.49%	0.04%	22.04%	23.82%	-6.91%	-0.89%	5.2%
Book Value per Share	9.72	11.83	10.67	11.18	11.27	13.57	16.73	15.64	15.53	16.37
Total Shareholders' Equity	59.54B	71.31B	63.41B	63.14B	63.24B	77.2B	95.66B	89.01B	88.2B	93.1B
Common Stock	461M	464M	467M	468M	470M	473M	476M	478M	480M	0
Retained Earnings	71.77B	85.29B	89.55B	97.67B	96.77B	103.39B	125.66B	118.35B	116.72B	0
Treasury Stock	-84.36B	-89.42B	-101.61B	-110.8B	-110.99B	-111.36B	-113.97B	-114.49B	-114.76B	0
Accumulated OCI	-11.04B	-9.32B	-11.28B	-11.64B	-11.69B	-5.9B	-8.3B	-7.96B	-7.84B	92.8B
Minority Interest	296M	348M	351M	303M	235M	262M	256M	274M	294M	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	15.9B	16.47B	15.83B	12.59B	14.4B	32.58B	29.27B	8.7B	12.74B	0
Operating CF Margin %	30.1%	31.34%	29.5%	30.57%	34.58%	40.08%	29.17%	14.61%	20.03%	-
Operating CF Growth %	9.57%	3.58%	-3.9%	-20.46%	14.42%	126.2%	-10.17%	-70.27%	46.48%	-100%
Net Income	7.25B	21.36B	11.19B	16.3B	7.02B	22.46B	31.4B	2.17B	8.05B	7.77B
Depreciation & Amortization	5.76B	6.27B	6.38B	6.01B	4.78B	5.19B	5.06B	6.29B	7.01B	0
Stock-Based Compensation	691M	840M	949M	718M	756M	1.18B	872M	525M	877M	0
Deferred Taxes	-700M	-2.41B	-2.21B	614M	-1.47B	-4.29B	-3.76B	-3.44B	-2.1B	0
Other Non-Cash Items	2.82B	-10.88B	437M	-7.03B	3.59B	-4.76B	150M	5.33B	1.97B	-7.77B
Working Capital Changes	85M	1.3B	-926M	-4.03B	-275M	12.8B	-4.46B	-2.17B	-3.07B	0
Change in Receivables	-134M	259M	-644M	-742M	-1.25B	-3.81B	261M	347M	-109M	0
Change in Inventory	365M	-357M	-717M	-1.05B	-736M	-1.13B	592M	6.2B	-854M	0
Change in Payables	871M	46M	431M	-564M	353M	1.24B	1.19B	-300M	-1.02B	0
Cash from Investing+	-7.81B	-4.74B	4.53B	-3.94B	-4.27B	-22.55B	-15.78B	-32.28B	2.65B	0
Capital Expenditures	-2B	-2.22B	-2.2B	-2.59B	-2.79B	-2.71B	-3.24B	-3.91B	-2.91B	0
CapEx % of Revenue	3.78%	4.22%	4.09%	6.3%	6.7%	3.34%	3.23%	6.56%	4.57%	-
Acquisitions	-18.37B	-1B	154M	-10.86B	-621M	-12M	-23B	-43.43B	7.04B	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	52M	650M	133M	206M	813M	-306M	3.77B	-180M	0	0
Cash from Financing+	-8.92B	-13.04B	-20.44B	-8.48B	-9.65B	-9.82B	-14.83B	26.07B	-17.14B	0
Debt Issued (Net)	2.61B	-941M	-935M	8.76B	-12.76B	-1.1B	-3.52B	35.95B	-7.16B	0
Equity Issued (Net)	-1000K	-1000K	-1000K	-1000K	0	0	-1000K	0	0	0
Dividends Paid	-7.32B	-7.66B	-7.98B	-8.04B	-8.44B	-8.73B	-8.98B	-9.25B	-9.51B	0
Share Repurchases	-5B	-5B	-12.2B	-8.87B	0	0	-2B	0	0	0
Other Financing	-229M	250M	-589M	-341M	11.55B	16M	-335M	-632M	-469M	0
Net Change in Cash	-1.05B	-1.25B	-206M	-50M	475M	158M	-1.51B	2.45B	-1.81B	-1.11B
Free Cash Flow+	13.9B	14.25B	13.63B	9.99B	11.61B	29.87B	26.03B	4.79B	9.84B	0
FCF Margin %	26.32%	27.12%	25.41%	24.27%	27.88%	36.74%	25.95%	8.05%	15.46%	-
FCF Growth %	6.81%	2.52%	-4.36%	-26.68%	16.19%	157.23%	-12.85%	-81.59%	105.2%	-100%
FCF per Share	2.26	2.35	2.28	1.76	2.06	5.23	4.54	0.84	1.73	-
FCF Conversion (FCF/Net Income)	2.20x	0.77x	1.42x	0.77x	1.57x	1.47x	0.93x	4.08x	1.59x	-
Interest Paid	1.45B	1.52B	1.31B	1.59B	1.64B	1.47B	1.44B	2.21B	3.23B	0
Taxes Paid	2.52B	2.49B	3.65B	3.66B	3.15B	7.43B	7.87B	3.15B	3.6B	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	11.56%	32.4%	16.47%	25.59%	14.43%	31.43%	36.18%	2.3%	9.02%	8.56%
Return on Invested Capital (ROIC)	10.78%	10.22%	10.55%	5.18%	6.39%	14.68%	23.19%	2.76%	7.93%	9.35%
Gross Margin	69.8%	69.97%	70.16%	69.34%	71.74%	57.67%	61.89%	50.95%	65.77%	70.33%
Net Margin	13.66%	40.55%	20.79%	39.52%	21.99%	27.25%	31.26%	3.58%	12.6%	12.42%
Debt / Equity	0.69x	0.59x	0.65x	0.80x	0.60x	0.48x	0.36x	0.79x	0.76x	-
Interest Coverage	12.04x	11.33x	11.62x	4.77x	6.27x	16.11x	30.33x	2.40x	5.33x	5.78x
FCF Conversion	2.20x	0.77x	1.42x	0.77x	1.57x	1.47x	0.93x	4.08x	1.59x	-
Revenue Growth	8.13%	-0.53%	2.1%	-23.25%	1.16%	95.16%	23.43%	-40.64%	6.84%	-1.65%

US Stock Screener

...

Pfizer Inc. (PFE) 10-Year Financial Performance & Capital Metrics

PFE •

HealthcareLarge PharmaVaccines and plasma-derived therapies

Revenue $62.58B -1.6%
EBITDA $20.34B -13.4%
Net Income $7.77B -3.1%
EPS (Diluted) 1.36 -3.5%
Gross Margin 70.33% +6.9%
EBITDA Margin 32.51% -12.0%
Operating Margin 24.67% -4.8%
Net Margin 12.42% -1.5%
ROE 8.56% -5.1%
ROIC 9.35% +17.9%
Debt/Equity -
Interest Coverage 5.78 +8.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓14 consecutive years of dividend growth
✓Healthy 5Y average net margin of 17.4%
✓Trading near 52-week high

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y2.51%

5Y8.48%

3Y-14.56%

TTM-1.65%

Profit (Net Income) CAGR

10Y1.1%

5Y-3.24%

3Y-37.2%

TTM-3.12%

EPS CAGR

10Y2.02%

5Y-3.51%

3Y-37.12%

TTM-3.42%

ROCE

10Y Avg10.78%

5Y Avg12.62%

3Y Avg7.32%

Latest9.35%

Peer Comparison

Vaccines and plasma-derived therapies

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
GRFSGrifols, S.A.	2.35B	9.10	33.54	9.41%	4.96%	4.92%	26.64%	1.17
PFEPfizer Inc.	157.21B	27.65	20.33	-1.65%	12.42%	8.35%
SNYSanofi	117.53B	48.66	20.32	5.49%	16.72%	10.9%	8.92%	0.30
MRKMerck & Co., Inc.	307.22B	123.78	17.00	1.31%	28.08%	35.17%
GSKGSK plc	118.65B	59.13	16.16	1.83%	17.86%	35.83%	6.6%	1.11

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	52.82B	52.55B	53.65B	41.17B	41.65B	81.29B	100.33B	59.55B	63.63B	62.58B
Revenue Growth %	8.13%	-0.53%	2.1%	-23.25%	1.16%	95.16%	23.43%	-40.64%	6.84%	-1.65%
Cost of Goods Sold+	15.95B	15.78B	16.01B	12.62B	11.77B	34.41B	38.24B	29.21B	21.78B	18.57B
COGS % of Revenue	30.2%	30.03%	29.84%	30.66%	28.26%	42.33%	38.11%	49.05%	34.23%	29.67%
Gross Profit+	36.87B	36.77B	37.64B	28.55B	29.88B	46.88B	62.09B	30.34B	41.85B	44.01B
Gross Margin %	69.8%	69.97%	70.16%	69.34%	71.74%	57.67%	61.89%	50.95%	65.77%	70.33%
Gross Profit Growth %	3.29%	-0.27%	2.37%	-24.15%	4.66%	56.88%	32.46%	-51.14%	37.92%	5.18%
Operating Expenses+	22.6B	22.38B	22.35B	21.04B	20.8B	26.08B	24.54B	25.05B	25.36B	28.58B
OpEx % of Revenue	42.78%	42.59%	41.66%	51.1%	49.93%	32.09%	24.46%	42.06%	39.86%	45.67%
Selling, General & Admin	14.76B	14.73B	14.38B	12.67B	11.4B	12.25B	13.12B	14.47B	14.73B	13.35B
SG&A % of Revenue	27.93%	28.04%	26.81%	30.78%	27.37%	15.07%	13.07%	24.3%	23.15%	21.33%
Research & Development	7.84B	7.64B	7.97B	8.36B	9.39B	13.83B	11.43B	10.58B	10.74B	11.98B
R&D % of Revenue	14.84%	14.55%	14.85%	20.31%	22.56%	17.01%	11.39%	17.76%	16.88%	19.14%
Other Operating Expenses	0	0	0	0	0	0	0	0	-105M	3.25B
Operating Income+	14.27B	14.39B	15.29B	7.51B	9.09B	20.79B	37.55B	5.29B	16.48B	15.44B
Operating Margin %	27.02%	27.39%	28.5%	18.24%	21.81%	25.58%	37.43%	8.89%	25.91%	24.67%
Operating Income Growth %	7.36%	0.82%	6.24%	-50.87%	20.96%	128.87%	80.58%	-85.91%	211.47%	-6.35%
EBITDA+	20.03B	20.66B	21.67B	13.31B	13.77B	25.98B	42.61B	11.58B	23.5B	20.34B
EBITDA Margin %	37.92%	39.32%	40.4%	32.32%	33.05%	31.97%	42.47%	19.45%	36.93%	32.51%
EBITDA Growth %	8.55%	3.14%	4.9%	-38.61%	3.46%	88.75%	64%	-72.82%	102.87%	-13.42%
D&A (Non-Cash Add-back)	5.76B	6.27B	6.38B	5.79B	4.68B	5.19B	5.06B	6.29B	7.01B	4.91B
EBIT	9.54B	13.57B	13.2B	13.06B	8.49B	25.6B	35.97B	3.27B	11.11B	10.19B
Net Interest Income+	-716M	-879M	-983M	-1.35B	-1.38B	-1.25B	-987M	-585M	-2.55B	-2.07B
Interest Income	470M	391M	333M	225M	73M	36M	251M	1.62B	545M	603M
Interest Expense	1.19B	1.27B	1.32B	1.57B	1.45B	1.29B	1.24B	2.21B	3.09B	2.67B
Other Income/Expense	-5.92B	-2.09B	-3.4B	3.97B	-2.05B	3.52B	-2.82B	-4.23B	-8.46B	-7.92B
Pretax Income+	8.35B	12.3B	11.88B	11.48B	7.04B	24.31B	34.73B	1.06B	8.02B	7.52B
Pretax Margin %	15.81%	23.42%	22.15%	27.9%	16.89%	29.91%	34.61%	1.78%	12.61%	12.02%
Income Tax+	1.12B	-9.05B	706M	618M	370M	1.85B	3.33B	-1.11B	-28M	-266M
Effective Tax Rate %	86.4%	173.14%	93.84%	141.69%	130.17%	91.1%	90.31%	201.61%	99.96%	103.32%
Net Income+	7.21B	21.3B	11.15B	16.27B	9.16B	22.15B	31.36B	2.13B	8.02B	7.77B
Net Margin %	13.66%	40.55%	20.79%	39.52%	21.99%	27.25%	31.26%	3.58%	12.6%	12.42%
Net Income Growth %	3.57%	195.29%	-47.65%	45.91%	-43.72%	141.81%	41.62%	-93.2%	276%	-3.12%
Net Income (Continuing)	7.23B	21.35B	11.18B	10.87B	6.67B	22.46B	31.4B	2.17B	8.05B	7.79B
Discontinued Operations	17M	-1M	10M	5.43B	2.53B	-268M	-1M	0	11M	25M
Minority Interest	296M	348M	351M	303M	235M	262M	256M	274M	294M	0
EPS (Diluted)+	1.17	3.52	1.87	2.87	1.63	3.88	5.47	0.37	1.41	1.36
EPS Growth %	5.09%	200.58%	-46.94%	53.67%	-43.29%	138.58%	41.01%	-93.22%	279.85%	-3.55%
EPS (Basic)	1.18	3.57	1.90	2.92	1.65	3.95	5.59	0.38	1.42	1.36
Diluted Shares Outstanding	6.16B	6.06B	5.98B	5.67B	5.63B	5.71B	5.73B	5.71B	5.7B	5.69B
Basic Shares Outstanding	6.09B	5.97B	5.87B	5.57B	5.55B	5.6B	5.61B	5.64B	5.66B	5.68B
Dividend Payout Ratio	101.41%	35.95%	71.53%	49.43%	92.15%	39.41%	28.64%	433.52%	118.6%	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	38.95B	41.14B	49.93B	32.8B	35.07B	59.69B	51.26B	43.33B	50.36B	0
Cash & Short-Term Investments	17.85B	19.99B	18.83B	9.65B	12.22B	31.07B	22.73B	12.69B	20.48B	0
Cash Only	2.6B	1.34B	1.14B	1.12B	1.79B	1.94B	416M	2.85B	1.04B	0
Short-Term Investments	15.26B	18.65B	17.69B	8.53B	10.44B	29.13B	22.32B	9.84B	19.43B	0
Accounts Receivable	11.27B	11.27B	11.4B	9.51B	11.18B	15.74B	14.53B	15.54B	14.78B	0
Days Sales Outstanding	77.85	78.29	77.56	84.29	97.95	70.7	52.86	95.27	84.77	-
Inventory	6.78B	7.58B	7.51B	7.07B	8.05B	9.06B	8.98B	10.19B	10.85B	0
Days Inventory Outstanding	155.18	175.32	171.19	204.37	249.49	96.08	85.72	127.31	181.84	-
Other Current Assets	3.05B	2.3B	12.19B	6.58B	3.65B	3.82B	5.02B	4.91B	4.25B	0
Total Non-Current Assets+	132.67B	130.65B	109.5B	134.69B	119.16B	121.78B	145.94B	183.17B	163.04B	0
Property, Plant & Equipment	13.32B	13.87B	13.38B	12.97B	13.74B	14.88B	16.27B	18.94B	18.39B	0
Fixed Asset Turnover	3.97x	3.79x	4.01x	3.17x	3.03x	5.46x	6.17x	3.14x	3.46x	-
Goodwill	54.45B	55.95B	53.41B	48.2B	49.56B	49.21B	51.38B	67.78B	68.53B	0
Intangible Assets	52.65B	48.74B	35.21B	33.94B	28.34B	25.15B	43.37B	64.9B	55.41B	0
Long-Term Investments	7.12B	7.01B	2.77B	20.15B	20.26B	21.53B	15.07B	15.37B	2.23B	0
Other Non-Current Assets	3.32B	3.23B	2.8B	17.63B	4.57B	7.68B	13.16B	12.47B	9.82B	0
Total Assets+	171.62B	171.8B	159.42B	167.49B	154.23B	181.48B	197.21B	226.5B	213.4B	0
Asset Turnover	0.31x	0.31x	0.34x	0.25x	0.27x	0.45x	0.51x	0.26x	0.30x	-
Asset Growth %	2.48%	0.11%	-7.2%	5.06%	-7.92%	17.67%	8.67%	14.85%	-5.79%	-100%
Total Current Liabilities+	31.11B	30.43B	31.86B	37.3B	25.92B	42.67B	42.14B	47.79B	42.99B	0
Accounts Payable	4.54B	4.66B	4.67B	3.89B	4.28B	5.58B	6.81B	6.71B	5.63B	0
Days Payables Outstanding	103.78	107.72	106.57	112.39	132.81	59.16	64.99	83.84	94.4	-
Short-Term Debt	10.66B	9.94B	8.84B	16.19B	2.7B	2.24B	2.93B	10.35B	6.95B	0
Deferred Revenue (Current)	0	0	0	0	1.11B	3.07B	2.52B	2.7B	1.51B	0
Other Current Liabilities	13.54B	13.32B	15.04B	14.14B	14.61B	28.27B	25.98B	23.32B	23.2B	0
Current Ratio	1.25x	1.35x	1.57x	0.88x	1.35x	1.40x	1.22x	0.91x	1.17x	-
Quick Ratio	1.03x	1.10x	1.33x	0.69x	1.04x	1.19x	1.00x	0.69x	0.92x	-
Cash Conversion Cycle	129.25	145.89	142.17	176.27	214.63	107.62	73.59	138.74	172.21	-
Total Non-Current Liabilities+	80.66B	69.71B	63.81B	66.84B	64.84B	61.34B	59.15B	89.42B	81.9B	-93.1B
Long-Term Debt	30.4B	32.67B	32.91B	34.65B	35.57B	34.76B	31.93B	60.5B	57.41B	0
Capital Lease Obligations	-12.17B	-27B	-21.35B	1.03B	0	0	0	0	2.29B	0
Deferred Tax Liabilities	30.75B	3.9B	3.7B	5.58B	4.06B	349M	1.02B	640M	2.12B	0
Other Non-Current Liabilities	19.51B	33.15B	27.2B	26.54B	25.2B	26.24B	26.2B	28.28B	20.09B	-93.1B
Total Liabilities	111.78B	100.14B	95.66B	104.15B	90.76B	104.01B	101.29B	137.21B	124.9B	-93.1B
Total Debt+	41.06B	42.61B	41.74B	50.84B	38.27B	37B	34.86B	70.84B	66.99B	0
Net Debt	38.47B	41.26B	40.61B	49.72B	36.49B	35.05B	34.44B	67.99B	65.95B	0
Debt / Equity	0.69x	0.59x	0.65x	0.80x	0.60x	0.48x	0.36x	0.79x	0.76x	-
Debt / EBITDA	2.05x	2.06x	1.93x	3.82x	2.78x	1.42x	0.82x	6.12x	2.85x	-
Net Debt / EBITDA	1.92x	2.00x	1.87x	3.74x	2.65x	1.35x	0.81x	5.87x	2.81x	-
Interest Coverage	12.04x	11.33x	11.62x	4.77x	6.27x	16.11x	30.33x	2.40x	5.33x	5.78x
Total Equity+	59.84B	71.66B	63.76B	63.45B	63.47B	77.46B	95.92B	89.29B	88.5B	93.1B
Equity Growth %	-7.94%	19.75%	-11.02%	-0.49%	0.04%	22.04%	23.82%	-6.91%	-0.89%	5.2%
Book Value per Share	9.72	11.83	10.67	11.18	11.27	13.57	16.73	15.64	15.53	16.37
Total Shareholders' Equity	59.54B	71.31B	63.41B	63.14B	63.24B	77.2B	95.66B	89.01B	88.2B	93.1B
Common Stock	461M	464M	467M	468M	470M	473M	476M	478M	480M	0
Retained Earnings	71.77B	85.29B	89.55B	97.67B	96.77B	103.39B	125.66B	118.35B	116.72B	0
Treasury Stock	-84.36B	-89.42B	-101.61B	-110.8B	-110.99B	-111.36B	-113.97B	-114.49B	-114.76B	0
Accumulated OCI	-11.04B	-9.32B	-11.28B	-11.64B	-11.69B	-5.9B	-8.3B	-7.96B	-7.84B	92.8B
Minority Interest	296M	348M	351M	303M	235M	262M	256M	274M	294M	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	15.9B	16.47B	15.83B	12.59B	14.4B	32.58B	29.27B	8.7B	12.74B	0
Operating CF Margin %	30.1%	31.34%	29.5%	30.57%	34.58%	40.08%	29.17%	14.61%	20.03%	-
Operating CF Growth %	9.57%	3.58%	-3.9%	-20.46%	14.42%	126.2%	-10.17%	-70.27%	46.48%	-100%
Net Income	7.25B	21.36B	11.19B	16.3B	7.02B	22.46B	31.4B	2.17B	8.05B	7.77B
Depreciation & Amortization	5.76B	6.27B	6.38B	6.01B	4.78B	5.19B	5.06B	6.29B	7.01B	0
Stock-Based Compensation	691M	840M	949M	718M	756M	1.18B	872M	525M	877M	0
Deferred Taxes	-700M	-2.41B	-2.21B	614M	-1.47B	-4.29B	-3.76B	-3.44B	-2.1B	0
Other Non-Cash Items	2.82B	-10.88B	437M	-7.03B	3.59B	-4.76B	150M	5.33B	1.97B	-7.77B
Working Capital Changes	85M	1.3B	-926M	-4.03B	-275M	12.8B	-4.46B	-2.17B	-3.07B	0
Change in Receivables	-134M	259M	-644M	-742M	-1.25B	-3.81B	261M	347M	-109M	0
Change in Inventory	365M	-357M	-717M	-1.05B	-736M	-1.13B	592M	6.2B	-854M	0
Change in Payables	871M	46M	431M	-564M	353M	1.24B	1.19B	-300M	-1.02B	0
Cash from Investing+	-7.81B	-4.74B	4.53B	-3.94B	-4.27B	-22.55B	-15.78B	-32.28B	2.65B	0
Capital Expenditures	-2B	-2.22B	-2.2B	-2.59B	-2.79B	-2.71B	-3.24B	-3.91B	-2.91B	0
CapEx % of Revenue	3.78%	4.22%	4.09%	6.3%	6.7%	3.34%	3.23%	6.56%	4.57%	-
Acquisitions	-18.37B	-1B	154M	-10.86B	-621M	-12M	-23B	-43.43B	7.04B	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	52M	650M	133M	206M	813M	-306M	3.77B	-180M	0	0
Cash from Financing+	-8.92B	-13.04B	-20.44B	-8.48B	-9.65B	-9.82B	-14.83B	26.07B	-17.14B	0
Debt Issued (Net)	2.61B	-941M	-935M	8.76B	-12.76B	-1.1B	-3.52B	35.95B	-7.16B	0
Equity Issued (Net)	-1000K	-1000K	-1000K	-1000K	0	0	-1000K	0	0	0
Dividends Paid	-7.32B	-7.66B	-7.98B	-8.04B	-8.44B	-8.73B	-8.98B	-9.25B	-9.51B	0
Share Repurchases	-5B	-5B	-12.2B	-8.87B	0	0	-2B	0	0	0
Other Financing	-229M	250M	-589M	-341M	11.55B	16M	-335M	-632M	-469M	0
Net Change in Cash	-1.05B	-1.25B	-206M	-50M	475M	158M	-1.51B	2.45B	-1.81B	-1.11B
Free Cash Flow+	13.9B	14.25B	13.63B	9.99B	11.61B	29.87B	26.03B	4.79B	9.84B	0
FCF Margin %	26.32%	27.12%	25.41%	24.27%	27.88%	36.74%	25.95%	8.05%	15.46%	-
FCF Growth %	6.81%	2.52%	-4.36%	-26.68%	16.19%	157.23%	-12.85%	-81.59%	105.2%	-100%
FCF per Share	2.26	2.35	2.28	1.76	2.06	5.23	4.54	0.84	1.73	-
FCF Conversion (FCF/Net Income)	2.20x	0.77x	1.42x	0.77x	1.57x	1.47x	0.93x	4.08x	1.59x	-
Interest Paid	1.45B	1.52B	1.31B	1.59B	1.64B	1.47B	1.44B	2.21B	3.23B	0
Taxes Paid	2.52B	2.49B	3.65B	3.66B	3.15B	7.43B	7.87B	3.15B	3.6B	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	11.56%	32.4%	16.47%	25.59%	14.43%	31.43%	36.18%	2.3%	9.02%	8.56%
Return on Invested Capital (ROIC)	10.78%	10.22%	10.55%	5.18%	6.39%	14.68%	23.19%	2.76%	7.93%	9.35%
Gross Margin	69.8%	69.97%	70.16%	69.34%	71.74%	57.67%	61.89%	50.95%	65.77%	70.33%
Net Margin	13.66%	40.55%	20.79%	39.52%	21.99%	27.25%	31.26%	3.58%	12.6%	12.42%
Debt / Equity	0.69x	0.59x	0.65x	0.80x	0.60x	0.48x	0.36x	0.79x	0.76x	-
Interest Coverage	12.04x	11.33x	11.62x	4.77x	6.27x	16.11x	30.33x	2.40x	5.33x	5.78x
FCF Conversion	2.20x	0.77x	1.42x	0.77x	1.57x	1.47x	0.93x	4.08x	1.59x	-
Revenue Growth	8.13%	-0.53%	2.1%	-23.25%	1.16%	95.16%	23.43%	-40.64%	6.84%	-1.65%

Pfizer Inc. (PFE) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare PFE vs Peers

vs MRK

vs GSK

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Pfizer Inc. (PFE) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare PFE vs Peers

vs MRK

vs GSK

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios